Laurie R. Lowdermilk, MSN, RN, ANP, CCRC


  • 1990-1993 / Barry University Miami, Florida, Master of Science in Nursing, Adult Nurse Practitioner
    1984-1988 / Oral Roberts University Tulsa, Oklahoma, Bachelor of Science in Nursing

Work Experience

  • 2008-Present / Adult Nurse Practitioner, Clinical Research Coordinator, Mountain Kidney and Hypertension Associates, PA
  • 2006-2008 / Clinical Research Coordinator, Asheville Gastroenterology Associates, PA
  • 1993-2006 / Adult Nurse Practitioner, Clinical Research Coordinator, Ira L. Lazar, MD, PA
  • 1989-1993 / Director of Nursing, Central Broward Acute Dialysis
  • 1988-1989 / Staff, Charge Nurse, North Ridge Medical Center


  • Adult Nurse Practitioner Certification American Academy of Nurse Practitioners
  • Certified Clinical Research Coordinator

Research Training

  • CITI Course in the Protection of Human Subjects, December 2006
  • CITI Refresher Course, January 2009

Hospital Affiliations

  • 2008-Present / Mission-St. Joseph's Health System
    509 Biltmore Avenue
    Asheville, NC 28801-4690


  • A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study Using XXXX and XXXX in Hyperphosphatemic Chronic Kidney Disease Patients on Hemodialysis
  • A Phase 3, Randomized, Active-Controlled, Open-Label, Multi-Center Study of the Safety and Efficacy of XXXX Injection for the Maintenance Treatment of Anemia in Hemodialysis Patients Previously Treated with XXXX
  • A Phase 2/3 Multi-Center, Randomized, Placebo-Controlled, Double-blind Study to Evaluate the Safety and Efficacy of XXXX Induction Therapy, Administered Subcutaneously, in Subjects with Moderately to Severely Active Ulcerative Colitis
  • A Multi-Center, Randomized, Double-Blind, Active-Control, 96 Week, Phase III Trial of the Efficacy and Safety of XXXX Compared with XXXX at Weeks 48 and 96 in Nucleoside Treatment-Naïve Patients with HBeAg Positive / Negative Chronic Hepatitis due to Hepatitis B Virus
  • A Multi-Center, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy, Safety and Tolerability of XXXX for 6 Months in Preventing Hepatic Encephalopathy
  • Assessment of the Efficacy of XXXX on Viral Kinetics, Cytokines, and Innate Immunity in a Group of Insulin Resistant, Treatment Naïve, Chronic Hepatitis C, Genotype 1 Patients
  • A Randomized, Multi-Center, Double-Blinded, Phase IV Study Evaluating the Efficacy (as measured by Sustained Virological Response) and Safety of XXXX In Combination with XXXX in Treatment-naïve Patients with Chronic Hepatitis C Genotype 1 Virus Infection of High Viral Titer and Baseline Body Weight Greater than or Equal to 85kg
  • A Multi-Centered, Prospective, Randomized, Placebo-Controlled Clinical Trial for the Treatment of Significant Steatosis or NASH with XXXX Followed by Treatment of Hepatitis C (HCV) with XXXX
  • A Study to Describe the Antiviral Effect of XXXX in Blacks/African Americans and Hispanics with Chronic Hepatitis B Virus (HBV) Infection Who are Nucleoside/tide-Naïve
  • A Phase 3 Multi-Center, Randomized, Placebo Controlled, Double-Blind Study to Evaluate the Efficacy of XXXX Vaccination in Adults on Hemodialysis
  • A Comparison Study of the Safety and Efficacy of XXXX Versus XXXX in Chronic Renal Failure Patients with Anemia
  • A Phase 4 Prospective, Randomized, Active Center, Double Blind, Double Dummy, Multi-Center Study Comparing the Survival Benefits of XXXX Relative to XXXX.
  • An Investigational Study to Obtain Clinical Data on the Safety and Efficacy of the XXXX Device in Vascular Access for Hemodialysis Patients
Back To Top